Physician-Scientist. Chief Research Officer @EngIPM. Gellert-John P. Leonard Scholar, Associate Professor @WeillCornell. Husband & father. RTs ≠ endorsements
Joined February 2015
- Tweets 13,072
- Following 8,536
- Followers 7,811
- Likes 88,049
687 Photos and videos
Pinned Tweet
7 Nov 2024
Good time to read our Tweetorial/ X-planation of our nature.com/articles/s41586-0… paper now featured on the cover of @Nature!
9 Oct 2024
🚀Big News! Excited to share our work “The Interplay of Mutagenesis and ecDNA Shapes Urothelial Cancer Evolution” published in @Nature! nature.com/articles/s41586-0…
ALT Artistic conceptualization of chromosomal DNA breakdown and extrachromosomal circular DNA (ecDNA). These ecDNA circles can drive resistance to therapy in bladder cancer. Credit: Ella Maru Studio, Inc. @Ella_Maru
2
15
112
23,572
Thank you @AmericanCancer for supporting our our research to advance treatments for patients with #BladderCancer at @FaltasLab @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer
bit.ly/4dWYzNW
2
15
450
Dr. Bishoy M. Faltas retweeted
May 28
Durvalumab BCG is FDA approved in high risk NMIBC , by hitting its DFS - HR 0.68 (plus a ~⬇️ cystectomy rate). OS & M1 data show these patients have low cancer mortality & IO has about a 10% chance of serious side effects. Therefore, this is not a treatment for all HR NMIBC IMO. It’s hard to know who to select. Inconsistency with other data for Sasanlimab atezo means there is no subset that consistently benefits. It will be interesting to see whom urologists recommend for treatment. #ASCO26 astrazeneca.com/content/astr…
2
51
104
6,151
Dr. Bishoy M. Faltas retweeted
May 28
@OncoAlert @FDAOncology approved durvalumab for BCG-naive HR NMIBC based on POTOMAC trial results (DFS as the primary endpoint) @UroDocAsh @spsutkaMD @siadaneshmand @MaxKates @BogdanaSchmidt @JoshMeeks @SpiessPhilippe @shilpaonc @karima_oualla @urotoday @BladderCancerUS
May 28
Durvalumab now @US_FDA ✅ for Non-Muscle Invasive Bladder cancer based off #POTOMAC: PhIII, BCG Durvalumab vs. BCG alone in BCG naive HR-NMIBC:
- DFS waiting maturity (HR: 0.68)
- 3yr mDFS 82% vs 77%
- MedOncs will now see HR-NMIBC
#gusm #OncTwitter
6
15
1,788
Dr. Bishoy M. Faltas retweeted
May 26
Every ASCO plenary drug started as an NIH grant nobody noticed.
This year’s 5 plenary drugs trace back to:
▫️2,762 NIH grants
▪️$803M in public science
▫️29-41 years of runway
Drugs need decades to mature.
So before you watch the ASCO plenary, look at the staircase.
Then ask: "which drugs will be missing from the 2031 version?"
- - - - -
Source: NIH RePORTER· @asco · via @Jori_health
- - - - -
2
28
66
5,490
Dr. Bishoy M. Faltas retweeted
Thank you for supporting #bladdercancer research Dr. Letai @NCIDirector.
The #BladderCancer cancer research community has done a lot with little, but the field is now at a true inflection point. We have a growing critical mass of investigators across institutions, including @WeillCornell @WCM_MeyerCancer and @IcahnMountSinai, working together to move basic science discoveries to the bedside.
With sustained and expanded NCI investment, bladder cancer care will be transformed. So much opportunity that needs the NCI’s support. @BladderCancerUS
The future of bladder cancer treatment will depend on better biomarkers, smarter combinations of therapies, and continued collaboration between researchers, clinicians, and patients. That work is happening now across the NCI-supported research community. go.nih.gov/6SzthBM
ALT Microscopic view of a papillary urothelial (transitional cell) carcinoma.
1
3
21
2,611
One more! Today we found out that @mark_farha @WCMUrology Resident and Faltas Lab member just received the 2026 @BladderCancerUS John Quale Travel Award! @WeillCornell
Today, on my birthday, I am overwhelmed with gratitude for my family, friends, colleagues and the privilege of doing science and caring for patients.
One of the best gifts I received today was seeing the fruits of mentorship: not one, but TWO members of the Faltas Lab, Rahul Singh PhD. and Jaekwon Kim MD, PhD, received $100K Young Investigator Awards. Congratulations, Rahul and Jaekwon, on your hard work, persistence, and success. Proud and grateful to be part of your journey! It took us a few tries to spell out YIA, but we managed in the end :)
#TeamScience #Mentorship
1
5
53
4,353
Today, on my birthday, I am overwhelmed with gratitude for my family, friends, colleagues and the privilege of doing science and caring for patients.
One of the best gifts I received today was seeing the fruits of mentorship: not one, but TWO members of the Faltas Lab, Rahul Singh PhD. and Jaekwon Kim MD, PhD, received $100K Young Investigator Awards. Congratulations, Rahul and Jaekwon, on your hard work, persistence, and success. Proud and grateful to be part of your journey! It took us a few tries to spell out YIA, but we managed in the end :)
#TeamScience #Mentorship
20
7
120
15,532
Looking forward to participating in this FDA workshop discussing contemporary issues in non-muscle invasive bladder cancer trial design and interpretation @chana_weinstock @pcvblack, @UroDocAsh, @FaltasLab, @h_alahmadie @slernerbcmedu1 @djmcconkey and the full panel today
May 4
Upcoming Workshop: Contemporary Issues in Non-Muscle Invasive Bladder Cancer (NMIBC) Trial Design & Interpretation
Join the FDA Oncology Center of Excellence for a workshop exploring key challenges and advances in NMIBC research.
fda.gov/news-events/fda-meet…
#NMIBC #BladderCancer
ALT FDA promotional graphic for a hybrid public workshop titled "Contemporary Issues in Non-Muscle Invasive Bladder Cancer," scheduled for May 18, 2026, from 12:30–4:30 PM at the FDA Great Room, White Oak Campus. A tricolor awareness ribbon in blue, yellow, and purple is displayed on the left side of the image. The FDA logo appears in the upper right corner.
5
17
1,683
Tomorrow!
Can distinct forms of transient genotoxic stress leave a lasting cellular memory that reprograms cells?
If you are curious about this question, come to my talk: “The Hidden Memory of DNA Damage: DASP in Bladder Cancer Evolution and Resistance” at the Society for Basic Urologic Research @UrologySBUR @AmerUrological #AUA2026. I will present a new story that my lab has been working on for a while!
Looking forward to seeing friends and colleagues and discussing #BladderCancer #DASP #CancerEvolution #AUA2026 #FaltasLab @WCMGUcancer @WeillCornell.
This session features a fantastic lineup of speakers spanning bladder, kidney, and prostate cancer biology.
1
423
Can distinct forms of transient genotoxic stress leave a lasting cellular memory that reprograms cells?
If you are curious about this question, come to my talk: “The Hidden Memory of DNA Damage: DASP in Bladder Cancer Evolution and Resistance” at the Society for Basic Urologic Research @UrologySBUR @AmerUrological #AUA2026. I will present a new story that my lab has been working on for a while!
Looking forward to seeing friends and colleagues and discussing #BladderCancer #DASP #CancerEvolution #AUA2026 #FaltasLab @WCMGUcancer @WeillCornell.
This session features a fantastic lineup of speakers spanning bladder, kidney, and prostate cancer biology.
1
4
17
1,606
Also, if you are looking for a postdoc position and attending AUA/SBUR, we are hiring!
Application instructions below, with the possibility of meeting there if there is a strong fit. x.com/FaltasLab/status/20232…
Please spread the word. We have open positions for outstanding postdoctoral researchers interested in studying the mechanisms of cancer evolution and new ways to intercept it!
#Hiring #Postdoc #ScienceTwitter #CancerResearch #CancerBiology
Details below:
3
857
Dr. Bishoy M. Faltas retweeted
May 6
Daraxonrasib in Previously Treated Advanced
RAS-Mutated #PancreaticCancer (Phase 1-2 study)
nejm.org/doi/pdf/10.1056/NEJ…
@RevMedicines @salmanpunekar
3
41
137
8,652
Dr. Bishoy M. Faltas retweeted
Please join us on May 18 for our NMIBC workshop. Honored to be joined by a wonderful lineup of panelists including @UroDocAsh @djmcconkey @garysteinbergmd @h_alahmadie @MaxKates @pjhensley11 @spsutkaMD @pcvblack @FaltasLab @MattGalsky @drdonnahansel @ERPlimackMD @SimaPorten
May 4
Upcoming Workshop: Contemporary Issues in Non-Muscle Invasive Bladder Cancer (NMIBC) Trial Design & Interpretation
Join the FDA Oncology Center of Excellence for a workshop exploring key challenges and advances in NMIBC research.
fda.gov/news-events/fda-meet…
#NMIBC #BladderCancer
ALT FDA promotional graphic for a hybrid public workshop titled "Contemporary Issues in Non-Muscle Invasive Bladder Cancer," scheduled for May 18, 2026, from 12:30–4:30 PM at the FDA Great Room, White Oak Campus. A tricolor awareness ribbon in blue, yellow, and purple is displayed on the left side of the image. The FDA logo appears in the upper right corner.
1
5
6
1,038
With hard work, focus, and the determination to finish what we start, I am sure there are many more achievements ahead of you. Keep up the good work Mohamed Osman !
#ProudPI
1
22
1,618
Dr. Bishoy M. Faltas retweeted
Apr 27
Relay announces data for Zovegalisib (PI3Ki) plus Atirmociclib (CDK4i) Triplet Combination in late line MBC: 44% ORR in heavily pre-treated, CDK4/6-experienced patients (median third-line). Plan to start a first-line phase 3 trial in 2026. globenewswire.com/news-relea…
3
26
89
8,145
It was great to see friends and colleagues at the #AACR26 annual grantee recognition event to receive the first @AACR Innovative Bladder Cancer Research Award!
Congratulations to #Faltaslab postdoc @MHosmanMD who received the AACR-EMD Serono fellowship and to my friend and colleague @efapostolou29 for her trailblazer award! Very well deserved @WCM_MeyerCancer @WCMDeptofMed @WeillCornell
5
5
49
3,963
@MHosmanMD also got to show @AACR_CEO Dr. Foti the tremendous impact of earlier @AACR support on his career. Thank you @AACR for supporting the careers of cancer researchers at all stages. Research saves lives!
2
1
11
600